Objective. To estimate the prevalence of non-adherence to rheumatoid arthritis (RA) medication and identify the associated factors for non-adherence in RA patients. Methods. Among the KORean Observational study Network for Arthritis 3,523 patients who completed a questionnaire about the adherence to RA medication were analyzed. The patients were divided into two groups: 1) adherent group, patients who skipped medication ≤5 days within the past 2 months; and 2) non-adherent group, patients who skipped ≥6 days of medication. The baseline characteristics were compared, and multivariable regression analysis was performed to identify the associated factors for non-adherence. Results. The non-adherent group had 339 patients (9.6%). The common causes of non-adherence were forgetfulness (45.8%), absence of RA symptoms (24.7%), and discomfort with RA medication (13.1%). Younger age (odds ratio [OR] 1.02, p＜0.01) and higher income (OR 1.70, p＜0.01) were associated with an increased risk of non-adherence. Whereas higher functional disability (OR 0.68, p＜0.01) and oral corticosteroid use (OR 0.73, p=0.02) were associated with a decreased risk of non-adherence. The associated factors differed according to cause of non-adherence. Having adverse events (OR 2.65, p=0.02) was associated with the risk of non-adherence due to discomfort with RA medication while a higher level of education (OR 2.37, p=0.03) was associated with the risk of non-adherence due to an absence of RA symptoms. Conclusion. The 9.6% of Korean RA patients were non-adherent to RA medication. The associated factors differed according to the cause of non-adherence. Therefore, an individualized approach will be needed to improve the adherence to RA medication. (J Rheum Dis 2018;25:47-57)
INTRODUCTION
Rheumatoid arthritis (RA) is a chronic inflammatory disease that leads to joint destruction, disability and premature mortality [1] . Current treatment guidelines for RA recommend early aggressive management with disease-modifying anti-rheumatic drugs (DMARDs) [2] .
The therapeutic approach for RA patients is mainly pharmacologic treatment, and therapeutic success is important for reducing symptoms, functional damage and joint deformity [3] . Therefore, RA patients require many pills that are DMARDs, corticosteroids, analgesics and non-steroidal anti-inflammatory drugs (NSAIDs). In addition, RA patients often have comorbidities due to the disease's chronic inflammatory mechanism. Thus, polypharmacy is more common than for other chronic diseases [4] , and patients can experience complications with their course of treatment. Drug adherence is important because it can affect disease outcome [5] . Drug adherence is defined as the extent to which a patient's behavior matches what is prescribed by healthcare providers [6] . The word "compliance" was used previously, but this focused on patient's passive role in following a doctor's order. Therefore, "adherence" is preferred by healthcare providers. Adherence suggests a patient's rights in a therapeutic alliance or contract with their doctors [6, 7] . Another term to explain the concept to taking medication is medication persistence which reflects continuously taking medications in a period of time [8] .
Previous studies report that drug adherence of RA patients is vary according to studies and detection tools; about 30% estimated by medication event monitoring system (MEMS) to 80% by medication possession ratio and patient self-reported questionnaire [9] [10] [11] [12] [13] . In addition, many studies report that factors such as socioeconomics, disease-specific factors, and psychological factors are associated with drug adherence in RA patients [14] [15] [16] [17] [18] . However, most factors showed conflicting results. Considering that there are various causes of non-adherence in RA patients, we assumed that the associated factors for non-adherence also have to be analyzed according to the cause of non-adherence. Therefore, the purpose of this study was to estimate the prevalence of non-adherence to RA treatment in Korean RA cohort, and identify associated factors for non-adherence according to specific causes in RA patients.
MATERIALS AND METHODS

Study population
Patients aged 18 or older who satisfied the 1987 American College of Rheumatology classification criteria for RA were recruited by rheumatologists in 23 centers during routine clinic visits as part of the KORean Observational study Network for Arthritis (KORONA) [19] . KORONA is a nationwide prospective multicenter cohort which enrolls RA patients from 23 rheumatology centers. Among patients enrolled in KORONA, only one patient who did not complete a questionnaire about adherence to RA treatment was excluded in this study.
Prevalence and causes of non-adherence to RA treatment
We evaluated the prevalence of drug adherence using a self-reported questionnaire. The question "How many days did you fail to take your medication in the preceding 60 days?" had a six-item scale response: 1) taken daily; 2) failed 1∼5 days; 3) failed 6∼15 days; 4) failed 16∼30 days; 5) failed 31 days or more; and 6) not prescribed any medication. We defined the adherent group as patients who skipped medication ≤5 days within the past 2 months and the non-adherent group as patients who skipped ≥6 days. Patients who were not prescribed any medication were excluded from analysis ( Figure 1 ).
In addition, we obtained the reasons for non-adherence to RA medication in a multiple-choice question: 1) for-getfulness; 2) absence of RA symptoms; 3) discomfort with RA medication; 4) taking an alternative treatment for RA; or 5) other.
Associated factors for non-adherence to RA treatment
We collected information about patient demographic profiles and socioeconomic status including family income per month and level of education. Disease-specific information collected in detail included disease duration, disease activity defined as disease-activity score for 28 joints-erythrocyte sedimentation rate (DAS28-ESR), functional disability as a health assessment questionnaire (HAQ) and comorbidities. Experience of adverse events (AEs) was defined as the previous experience of any AEs since starting RA medication. Experience of AEs consisted of gastrointestinal (GI) AEs including stomachache, nausea/vomiting, dermatologic AEs such as alopecia, pruritus, and other AEs.
For medications, type of RA and osteoporotic medication and number of daily and weekly medications were collected. Detailed interviews and joint assessment were performed by rheumatologists or trained health professionals. Information about laboratory tests and medications were collected by medical chart review. 
Review
Ethical considerations
The study protocol was approved by the Institutional Review Board of Hanyang University Hospital (HYUH 2009-04-003, HYUH 2013-09-006) and other centers included in this study. Written informed consent was provided by each patient.
Statistical analysis
After estimating the prevalence of non-adherent group patients, we compared their demographic and clinical characteristics using chi-square tests and Student t-tests.
To identify associated factors for non-adherence in RA patients, we performed crude and multivariable logistic regression analysis using socioeconomic and clinical information that can affect adherence to RA medication. Since there is no gold standard of definition for non-adherence, we performed a sensitivity analysis using a definition of non-adherent group as patients who skipped ≥ 16 days. And then we further analyzed associated factors for non-adherence due to absence of RA symptoms and discomfort with RA medication in non-adherent patients. All analyses were performed using IBM SPSS software version 20.0 (IBM Co., Armonk, NY, USA). Results were considered statistically significant when p-values were less than 0.05.
RESULTS
Patient characteristics
Mean age of patients in this study was 54.2 years and 85.7% were female (Table 1 ). Mean disease duration was 8.6 years and mean disease activity was 3.7 estimated by DAS28-ESR. In addition, 83.3% of patients were using methotrexate (MTX), and 5.9% were using biologic agents.
Prevalence of non-adherence
Among 3,523 patients included in analysis, 3,184 (90.4%) of RA patients were in the adherent group and 339 (9.6%) were in the non-adherent group (Table 1) . Patients in the non-adherent group were younger (50.9±12.6 years, non-adherent vs. 54.6±11.7 years, adherent, p＜0.01), and had higher income. More patients in the non-adherent group reported ever-experience of AEs (44.2% vs. 33.3%, p＜0.01). In addition, patients in the non-adherent group had lower HAQ score (0.57±0.57 vs. 0.68±0.65, p＜0.01), but fewer had hypertension (19.8% vs. 25.9%, p=0.02) or diabetes mellitus (DM) (3.5% vs. 8.5%, p＜0.01) compared with the adherent group. Fewer patients in the non-adherent group were using oral corticosteroids (68.7% vs. 74.2%, p=0.04) or biologic agents (3.2% vs. 6.5%, p=0.04); MTX, other DMARDs, NSAIDs/painkillers, and the number of daily or weekly medications did not vary between the two groups. We collected the cause of non-adherence to RA medication using a multiple-choice question ( Figure 2 ). Common causes of non-adherence in the non-adherent group were forgetfulness (45.8%), absence of RA symptoms (24.7%), taking an alternative treatment for RA (14.6%), and dis- comfort with RA medication (13.1%).
Associated factors for non-adherence in RA patients
To identify associated factors for non-adherence in RA patients, we performed crude and multivariable logistic regression analysis (Table 2) . In crude analysis, younger age, female sex, and higher income were associated with non-adherence in RA patients. Patients who experienced GI AEs or with depression were at increased risk of non-adherence. Having hypertension or DM, or factors representing severe disease such as higher HAQ, or using oral corticosteroids or biologic agents were protective factors against non-adherence in RA patients.
After adjusting for variables, younger age (OR 1.02, 95% confidence interval [CI] 1.01∼1.04, p＜0.01), higher income (OR 1.71, CI 1.16∼2.52 for income ≥5,000 dollars per month, p＜0.01), experience of GI AEs (OR 1.83, CI 1.40∼2.38, p＜0.01), and higher DAS28-ESR (OR 1.13, Figure 2 . Causes of non-adherence in rheumatoid arthritis (RA) patients. CI 1.01∼1.26, p=0.03) were associated with increased the risk of non-adherence. Factors representing severe disease including higher functional disability (OR 0.67, CI 0.52∼0.87, p＜0.01), and using oral corticosteroids (OR 0.73, CI 0.55∼0.96, p=0.02) were associated with decreased risk of non-adherence. The results of analysis using definition of non-adherent group as patients who skipped ≥16 days were almost identical to the definition of non-adherence as patients who skipped ≥6 days (data not shown). We further performed crude and multivariable regression analysis of associated factors for non-adherence according to intentional causes in non-adherent patients (Table 3) . In adjusted analysis, having GI AEs (OR 2.44, CI 1.13∼5.26, p=0.02) was associated with increased risk of non-adherence due to discomfort with RA medication. Higher level of education (OR 2.23, CI 1.03∼ 4.81, p=0.04) was associated with increased risk of non-adherence due to absence of RA symptoms without medication.
DISCUSSION
In this study, 9.6% of RA patients were defined as non-adherent due to not taking their medication 6 or more days out of 60. Younger age, higher income, and experience of GI AEs were associated with increased risk of non-adherence. Having severe disease, as represented by higher functional disability and using oral corticosteroids, were associated with decreased risk of non-adherence in RA patients. Associated factors differed according to the cause of non-adherence: having GI AEs was associated with increased risk of non-adherence due to discomfort with RA treatment, while higher level of education was associated with increased risk of non-adherence due to absence of RA symptoms.
Previous studies reported about the adherence and associated factors affecting medication adherence in RA patients (Table 4) [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] . In these studies, adherence rate, the ways to estimate drug adherence, and definitions of adherence differed between studies. Although we expected that adherence rate estimated using electronic monitor such as MEMS will be lower than self-reported questionnaire, we could not find any definite difference of adherence rate in different ways to estimate drug adherence. The most feasible way to estimate drug adherence was self-reported measures. Compared to other measurement methods such as drug pill counts, electronic monitors, rates of refilling prescriptions, or sample assays of drug levels or drug byproducts, self-reported measures are easy, speedy, flexible and have low cost burden [6, 30, 31] . We used self-reported measures as two related questionnaires, and showed moderate correlation between the two questionnaires (data not shown). Among the questionnaires, we selected more objective questions that asked the number of days the patient failed to take their medication, and defined non-adherence failure to take medication 6 days or more. Compared to previous studies, the adherence rate of 90.4% is quite high [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] . We assumed that this result was due to the characteristics of the patient cohort rather than our method of estimation. The patients in this cohort generally have good relationships with doctors, have insight into their disease, and are cooperative. As such, they may have good adherence to medication.
Similar to a previous study that reported that older patients have higher adherence and patients who are busy tend to have lower adherence [14, 32] , we found that younger age was associated with non-adherence in RA patients. In this study, experiencing AEs was also associated with non-adherence in RA patients. We propose that experiencing AEs affects beliefs about medications, such as the general harm of medications, which are associated with drug adherence [10, 16] . In contrast, variables that represent severe disease such as higher HAQ and use of oral corticosteroids had protective effects against non-adherence; these results were consistent with previous studies [16, 32] . Interestingly, higher DAS28-ESR was associated with non-adherence; in contrast, higher HAQ and use of oral corticosteroids were protective factors against non-adherence. Since it is well-known that high disease activity is associated with the use of oral corticosteroids or high disability measured by high HAQ score [33, 34] , this result was somewhat surprising. Several studies report conflicting results with regard to disease activity [5, 32] . In one study, higher disease activity was a predictive factor for drug adherence. On the other hand, another study found that non-adherence leads to high disease activity. Since our study has a cross-sectional design, higher disease activity as an associated factor for non-adherence could be the result of non-adherence. Moreover, our multivariable analyses of associated factors for non-adherence due to each cause showed that (1) Multivariable (2) Multivariable (1) Multivariable (2) OR (95% CI) Values are presented as mean±standard deviation or number (%), and bold value indicates statistical significance at the 0.05 level. RA: rheumatoid arthritis, OR: odds ratio, CI: confidence interval, DAS28-ESR: disease activity score 28 joints-erythrocyte sedimentation rate, HAQ: health assessment questionnaire, NSAIDs: non-steroidal anti-inflammatory drugs. [10, 16, 35] . The studies showed conflicting results about associations between polypharmacy and drug adherence. We also analyzed the effect of the number of daily and weekly medications and dietary supplements on drug adherence; we found no association between them.
To find causes of non-adherence, non-adherence can be divided into two subtypes: unintentional (due to forgetfulness, regimen complexity or physical problems) and intentional (based on the patient's decision to take no/less medication) [18] . In this study, forgetfulness was most frequent cause of non-adherence. In addition, many patients showed intentional non-adherence, discomfort with RA medication or absence of RA symptoms. According to a previous review, patients with intentional nonadherence may make a benefit-risk analysis, weighing the perceived risks of treatment against the perceived benefits [18] . We assumed that demographic and clinical characteristics would be different between patients who experienced discomfort with RA medication and absence of RA symptoms. Thus, we further analyzed factors associated with non-adherence due to specific causes. As we hypothesized, factors associated with non-adherence for each cause differed. Experiencing GI AEs was associated with increased risk of non-adherence due to discomfort with RA medication, while GI AEs had protective effects against non-adherence due to the absence of RA symptoms. Although the questionnaire asking cause of non-adherence was multiple-choice question, patients who experience AEs tend to choose ' AEs due to RA medication' as the cause of non-adherence (data not shown). In addition, having NSAIDs/painkillers showed protective effects against non-adherence due to discomfort with RA medication, but no significant association was seen between any medication and non-adherence due to the absence of RA symptoms. More patients without NSAIDs/painkillers identified the cause of their non-adherence as ' AEs due to RA medication' than patients with NSAIDs/painkillers, while there was no difference in 'absence of RA symptoms'. Among comorbidities, only DM showed positive effect on adherence. We think there are two possibilities. First, DM and RA are chronic diseases which need regular medication regardless of symptoms. Therefore, patients with DM and RA undergo frequent education about medication.
Second, RA patients with glucocorticoid, which increase the blood glucose level, are strictly educated to have regular medication of DM from their doctor. This careful management can have positive effect of medication adherence. However, the relationship has to be revealed in future study. Differences in associated factors for non-adherence due to all causes, older age and higher level of education were associated with risk of non-adherence due to absence of RA symptoms. Although many studies found that younger age is associated with non-adherence but education was not [15, 16] , we also know that patient knowledge, self-efficacy, and beliefs about the disease and its treatment influence adherence [10, 15, 16] . Therefore, among intentional non-adherence, especially when RA symptoms were absent without medication, patients with more experience and knowledge weigh benefits and risks for RA treatment and then decide not to take medicine.
In this study, we found that causes of non-adherence varied and differed according to patient profile and disease status. Thus, uniform efforts to raise adherence could cause the reverse effect. Considering our results, we suggest patient education or reminder systems for patients who tend to be forgetful about medication. In addition, for patients who experience GI AEs, we should prescribe a more careful combination of medications or doses to minimize AEs. In patients without RA symptoms, rapid decreases in medication through doctor-patient communication are needed, especially for patients who are young and have high levels of education.
This study has several strengths. First, we analyzed associated factors for non-adherence according to causes, and found that associated factors differed according to the cause of non-adherence. We assert that non-adherence must be considered on an individual basis. Second, compared to previous studies, we used a larger observational cohort that could better represent the RA patient population. However, we also had several limitations. First, self-reported questionnaires were used to identify adherence in RA patients. This method is useful for large groups of patients, but is not as accurate as other objective methods. Second, since our study had a cross-sectional design, we could not report definite causal relationships between several associated factors and non-adherence. Further study is needed using a prospective study design for conclusive results.
